Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrated Diagnostics HoldingsLSE:IDHC 58 5-Year Yield-on-Cost % is 1.67 as of Jul. 18, 2026, which is 64% below its 10-year median of 4.70. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.59 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks worse than 65.63% on this metric.
The historical rank and industry rank for Integrated Diagnostics Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
LSE:IDHC'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.64 Med: 4.7 Max: 31.54
Current: 1.67
During the past 13 years, Integrated Diagnostics Holdings's highest Yield on Cost was 31.54. The lowest was 1.64. And the median was 4.70.
LSE:IDHC's 5-Year Yield-on-Cost % is ranked worse than 65.63% of 64
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.54
vs LSE:IDHC: 1.67
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Integrated Diagnostics Holdings 5-Year Yield-on-Cost % Related Terms
LSE:IDHC vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrated Diagnostics Holdings 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Integrated Diagnostics Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Integrated Diagnostics Holdings (LSE:IDHC) has a 5-Year Yield-on-Cost % of 1.67 as of Jul. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Integrated Diagnostics Holdings and its competitors. This is 64% below median its historical median of 4.70. Over the past decade, Integrated Diagnostics Holdings' 5-Year Yield-on-Cost % has ranged from 1.64 to 31.54. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #42 out of 64 companies in the Medical Diagnostics & Research industry, placing it in the top 65.6%.
Is Integrated Diagnostics Holdings' 5-Year Yield-on-Cost % too high?
Integrated Diagnostics Holdings' current 5-Year Yield-on-Cost % of 1.67 is 64% below median its 10-year median of 4.70. Over the past 10 years, this metric has ranged from a low of 1.64 to a high of 31.54. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.54. Integrated Diagnostics Holdings' value of 1.67 is 34.3% below this industry median. Based on the distribution chart, Integrated Diagnostics Holdings ranks #42 out of 64 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #42 out of 64 companies for 5-Year Yield-on-Cost %. This places Integrated Diagnostics Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.54. Integrated Diagnostics Holdings' value of 1.67 is 34.3% below this benchmark. Historically, Integrated Diagnostics Holdings' own 5-Year Yield-on-Cost % has ranged from 1.64 to 31.54 over the past decade. While the company's 10-year median is 4.70 vs. the industry median of 2.54, Integrated Diagnostics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.54, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrated Diagnostics Holdings's current 5-Year Yield-on-Cost % of 1.67 is 34.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Integrated Diagnostics Holdings and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrated Diagnostics Holdings's current 5-Year Yield-on-Cost % is 1.67, which is 64% below median its own 10-year median of 4.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.59, compared to a current price of $0.51 — trading 13.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.67, which is 64% below median its 10-year median of 4.70 and 34.3% below the Medical Diagnostics & Research industry median of 2.54. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current 5-Year Yield-on-Cost % is 1.67 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued.
The current stock price of $0.51 is trading 13.6% below its estimated GF Value™ of $0.59.
GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.
Key valuation signals for LSE:IDHC:
5-Year Yield-on-Cost %: 1.67 (64% below median its 10-year median of 4.70)
GF Value™: $0.59 vs. price of $0.51 (13.6% below fair value)
Industry Position: 34.3% below the Medical Diagnostics & Research median (#42 of 64)
No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrated Diagnostics Holdings Business Description
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score
Get the complete analysis for LSE:IDHC
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IDHC has been successfully added to your 
